Who Pays My Doctor?

Healthcare provider profile · identity verified

Eric Richard Thomason, NP

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · PITTSBURG, KS · NPI 1528425501

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Eric Richard Thomason, NP received $115,077.11 in general payments during 2025 across 268 reported records.

Otsuka America Pharmaceutical, Inc. accounted for 65.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 13 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$115,077.11

268 reported records · 10 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $74,951.3365.1%1672025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $34,400.4229.9%672025
Alkermes, Inc. Unresolved — no canonical attribution shown $4,942.204.3%152025
Lundbeck LLC Unresolved — no canonical attribution shown $280.040.2%22025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $172.540.1%82025
Teva Pharmaceuticals USA, Inc. Unresolved — no canonical attribution shown $147.510.1%52025
Dexcom, Inc. Unresolved — no canonical attribution shown $122.930.1%12025
Janssen Pharmaceuticals, Inc Unresolved — no canonical attribution shown $26.090.0%12025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $20.290.0%12025
Braeburn Inc. Unresolved — no canonical attribution shown $13.760.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$76,792.2049
Consulting Fee$19,521.0021
Travel and Lodging$13,973.7887
Food and Beverage$4,790.13111

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
REXULTI
Normalized: rexulti		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc. $39,274.07 84 2025
Source payment records
ABILIFY ASIMTUFII
Normalized: abilify asimtufii		 Drug Otsuka America Pharmaceutical, Inc. $32,933.77 77 2025
Source payment records
ABILIFY MAINTENA
Normalized: abilify maintena		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc. $29,530.59 62 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $27,504.42 61 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $4,942.20 15 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $1,767.66 11 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $172.54 8 2025
Source payment records
AUSTEDO XR
Normalized: austedo xr		 Drug Teva Pharmaceuticals USA, Inc. $147.51 5 2025
Source payment records
DEXCOM G7 GSS (161)
Normalized: dexcom g7 gss 161		 Medical Supply Dexcom, Inc. $122.93 1 2025
Source payment records
DEXCOM STELO GLUCOSE BIOSENSOR
Normalized: dexcom stelo glucose biosensor		 Not specified Dexcom, Inc. $122.93 1 2025
Source payment records
SPRAVATO
Normalized: spravato		 Drug Janssen Pharmaceuticals, Inc $26.09 1 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20.29 1 2025
Source payment records
BRIXADI
Normalized: brixadi		 Drug Braeburn Inc. $13.76 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
REXULTI
rexulti		 2025 Rexulti 2024 18
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
Lundbeck LLC
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
71829 supporting records · 25812 recipient NPIs · example record 1251759986 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 18 suppressed by CMS
Otsuka America Pharmaceutical, Inc.
Exact reporting entity; no affiliate inference		 2025 REXULTI
open payments reported associated product		 CMS Open Payments — General Payments
160756 supporting records · 46288 recipient NPIs · example record 1227267708 		Rexulti · 2024
Exact normalized brand match · 1 Part D row		 18 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Trazodone HclTrazodone Hcl7014
Buspirone HclBuspirone Hcl6812
Sertraline HclSertraline Hcl59suppressed
VraylarCariprazine Hcl41suppressed
GabapentinGabapentin4011
Lithium CarbonateLithium Carbonate29suppressed
AripiprazoleAripiprazole26suppressed
Duloxetine HclDuloxetine Hcl26suppressed
Hydroxyzine PamoateHydroxyzine Pamoate26suppressed
Quetiapine FumarateQuetiapine Fumarate26suppressed
Fluoxetine HclFluoxetine Hcl24suppressed
Propranolol HclPropranolol Hcl22suppressed
LamotrigineLamotrigine19suppressed
RexultiBrexpiprazole18suppressed
ClonazepamClonazepam17suppressed
Divalproex SodiumDivalproex Sodium17suppressed
Quetiapine Fumarate ErQuetiapine Fumarate15suppressed
Venlafaxine Hcl ErVenlafaxine Hcl14suppressed
MirtazapineMirtazapine13suppressed
IngrezzaValbenazine Tosylate12suppressed
LorazepamLorazepam12suppressed
LoxapineLoxapine Succinate12suppressed
Prazosin HclPrazosin Hcl12suppressed
Trihexyphenidyl HclTrihexyphenidyl Hcl12suppressed
BelsomraSuvorexant11suppressed
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11suppressed
OxcarbazepineOxcarbazepine11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $115,077.11 · 268 records Otsuka America Pharmaceutical, Inc. ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, BRIXADI, CAPLYTA, COBENFY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, LYBALVI, REXULTI, SPRAVATO 2 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error